As per the long term follow-up datar, at a median follow-up of 35.1 months, the median OS and PFS were 40.5 and 9.3 month respectively. The estimated 5-year OS and PFS rates were 41% and 22% respectively.
34/102 (33%) achieved CR on study.
In those achieving CR, median response duration was not reached, while the 5 year OS was 64% and PFS 52%. Of the 13/34 patients achieving CR who then remained in CR at study close, 4 had undergone allogeneic transplant, while 9 had received no further therapy. A number of patients who relapsed after discontinuing brentuximab vedotin in remission were rechallenged with brentuximab vedotin.r Of 21 retreated patients, there was a 60% second objective response rate (CR 30%).
Note that there is evidence that some patients can respond to retreatment with brentuximab after having previously discontinued brentuximab therapy.r
© Journal of Clinical Oncology 2012
© Blood 2016